Bentley Systems press release ( BSY ): Q4 Non-GAAP EPS of $0.27 beats by $0.01 . Revenue of $391.6M (+11.9% Y/Y) beats by $9.81M . Subscriptions revenues were $356.6 million, up 13.0% or 10.8% on a constant currency basis, year-over-year; Annualized Recurring Revenues (“ARR”) were $1,462.1 million
Bentley Systems press release ( BSY ): Q4 Non-GAAP EPS of $0.27 beats by $0.01 . Revenue of $391.6M (+11.9% Y/Y) beats by $9.81M . Subscriptions revenues were $356.6 million, up 13.0% or 10.8% on a constant currency basis, year-over-year; Annualized Recurring Revenues (“ARR”) were $1,462.1 million
Kymera Therapeutics press release ( KYMR ): Q4 GAAP EPS of -$0.97 misses by $0.18 . Revenue of $2.9M (-60.8% Y/Y) misses by $11.9M . More on Kymera Therapeutics Kymera Therapeutics: The More This Biotech Spends, The Higher Its Valuation Rises Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annu...
Kymera Therapeutics press release ( KYMR ): Q4 GAAP EPS of -$0.97 misses by $0.18 . Revenue of $2.9M (-60.8% Y/Y) misses by $11.9M . More on Kymera Therapeutics Kymera Therapeutics: The More This Biotech Spends, The Higher Its Valuation Rises Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Kymera Therapeutics Q4 2025 Earnings Preview Kymera Therapeutics prices $602M public offering at $86.00 a share
Vital Farms press release ( VITL ): Q4 GAAP EPS of $0.35 misses by $0.04 . Revenue of $213.6M (+28.7% Y/Y) beats by $0.77M . Gross Margin of 35.8%, compared to 36.1% Net Income of $16.3 million, compared to $10.6 million Net Income per
Vital Farms press release ( VITL ): Q4 GAAP EPS of $0.35 misses by $0.04 . Revenue of $213.6M (+28.7% Y/Y) beats by $0.77M . Gross Margin of 35.8%, compared to 36.1% Net Income of $16.3 million, compared to $10.6 million Net Income per
The value of collateral assets used by banks for commercial property loans is expected to continue declining in 2026, according to S&P Global Ratings, as the sector has yet to find a clear bottom. “More collateral pain is likely this year for Hong Kong banks,” the credit rating agency said in a report published on Thursday, adding that a subset of small banks could face more acute strain. That ass...
The value of collateral assets used by banks for commercial property loans is expected to continue declining in 2026, according to S&P Global Ratings, as the sector has yet to find a clear bottom. “More collateral pain is likely this year for Hong Kong banks,” the credit rating agency said in a report published on Thursday, adding that a subset of small banks could face more acute strain. That assessment comes as Hong Kong’s commercial property market remains on a sustained downturn that started...
Dragos Condrea/iStock via Getty Images Intro We last wrote on Kforce Inc . ( KFRC ) in September of last year when we downgraded the stock to a 'Sell' due to a significant trend-line breach, negative revenue growth, and bearish EPS revisions. To recap, Kforce is a professional US-based staff solutions provider that operates in both the technology and Finance and Accounting (FA) segments. The recen...
Dragos Condrea/iStock via Getty Images Intro We last wrote on Kforce Inc . ( KFRC ) in September of last year when we downgraded the stock to a 'Sell' due to a significant trend-line breach, negative revenue growth, and bearish EPS revisions. To recap, Kforce is a professional US-based staff solutions provider that operates in both the technology and Finance and Accounting (FA) segments. The recent muted performance of the more important tech segment (due to higher bill rates and revenues) was also a crucial factor in our downgrade of the stock. Although shares have lost solely 4% since our rating downgrade, we believe further downside is plausible for the following reasons. Bullish Reaction To Q3 Earnings Release Not Repeated For Q4 Shares actually delivered a much-needed respite on the release of the company's Q3 earnings (11/3/2025) when GAAP earnings of $0.63 per share surprised to the upside by 11%+. As alluded to earlier, the main precursor for the post-earnings rally was the improvement in working consultants in the technology segment. Furthermore, the fact that the company's Q3 release came well into the fourth quarter, management's expectations were high that tech momentum (With respect to customer-led AI solutions) at the time would continue over the following two months of the fourth quarter until the end of December 2025. Although management talked up the revenue beat in the fourth quarter (Q4 earnings released 2/2/2026), investors seemed to key more into the bottom-line result (GAAP earnings of $0.30 per share), which missed the consensus estimate by quite a margin ($0.17 per share). Furthermore, the outlook for Q1 was not very encouraging, given that management left the possibility of one-time items emerging in the three months open. Forward-Looking Guidance Growth Concerns On the Q4 earnings call, management cited a Q1 top-line expectation of approximately $328 million, which, if met, would be approximately $2 million short of Q1 of fiscal 2025 ($330 ...
Gargolas/iStock via Getty Images NextEra Energy ( NEE ) -1% pre-market Thursday after saying it plans to sell $2B of equity units in a public offering , with an underwriters option to purchase up to an additional $300M of equity units to cover any over-allotments. Each equity
Gargolas/iStock via Getty Images NextEra Energy ( NEE ) -1% pre-market Thursday after saying it plans to sell $2B of equity units in a public offering , with an underwriters option to purchase up to an additional $300M of equity units to cover any over-allotments. Each equity
Down 70% over the past year -- and down 60% over just the last three months -- Hims & Hers Health (NYSE: HIMS) stock is in a funk, and Monday night's earnings report didn't help. Shares of the telemedicine company have slid steadily since the FDA announced early last year that Novo Nordisk 's (NYSE: NVO) Wegovy and Ozempic GLP-1 weight loss drugs are no longer in shortage. Since that news came out...
Down 70% over the past year -- and down 60% over just the last three months -- Hims & Hers Health (NYSE: HIMS) stock is in a funk, and Monday night's earnings report didn't help. Shares of the telemedicine company have slid steadily since the FDA announced early last year that Novo Nordisk 's (NYSE: NVO) Wegovy and Ozempic GLP-1 weight loss drugs are no longer in shortage. Since that news came out, the writing has seemed to be on the wall for Hims & Hers Health and its business of compounding copycat weight loss drugs for direct sale to patients. Throw in a bit of price competition from branded manufacturers of GLP-1 drugs, Novo Nordisk and Eli Lilly (NYSE: LLY) , who have cut prices as much as 80%, and Hims' growth slowed significantly in the fourth quarter of 2025. Continue reading
Shares in Baidu were sliding on Thursday after weak advertising spending dragged down the Chinese search-engine provider’s profit and revenue. Baidu’s American depositary receipts dropped 2.7% to $129.80 ahead of the opening bell. Baidu reported fourth-quarter net income of 1.78 billion yuan ($255 million) on revenue of 32.74 billion yuan.
Shares in Baidu were sliding on Thursday after weak advertising spending dragged down the Chinese search-engine provider’s profit and revenue. Baidu’s American depositary receipts dropped 2.7% to $129.80 ahead of the opening bell. Baidu reported fourth-quarter net income of 1.78 billion yuan ($255 million) on revenue of 32.74 billion yuan.
JHVEPhoto/iStock Editorial via Getty Images Taylor Morrison Home Corporation ( TMHC ) has essentially gone nowhere since I wrote about it as my top pick for the bearish-to-bullish reversal in the stocks of home builders . That reversal lasted just another few more weeks before builders sank into another bear market (based on price levels for the iShares US Home Construction ETF (ITB)). That fresh ...
JHVEPhoto/iStock Editorial via Getty Images Taylor Morrison Home Corporation ( TMHC ) has essentially gone nowhere since I wrote about it as my top pick for the bearish-to-bullish reversal in the stocks of home builders . That reversal lasted just another few more weeks before builders sank into another bear market (based on price levels for the iShares US Home Construction ETF (ITB)). That fresh sell-off was timely as it provided a good risk/reward entry for the seasonal trade in home builders . Since accumulating shares in TMHC, I traded against the current price range, mainly by selling call options near the highs. Last week, 40% of my position was finally called away. This week, I started buying shares again after TMHC fell as much as 4.5% in the wake of the President reiterating his call for a ban on institutional purchases of single-family homes. More price discounts could be on the way given the tepid feel of TMHC’s latest earnings . While TMHC has had a strong start to the year, it is mainly a range-bound stock ( tradingview.com ) Tepid Guidance TMHC traded positively in the days following its earnings report. Perhaps the market was relieved that the tepid guidance was not worse. Overall, the company projected declines in 2026 as a focus continues on tight inventory management (spec count declined 11% from Q3 to Q4) and returning “excess capital” to shareholders. Here are some key comparisons between 2026 guidance and 2025 results with the percent changes in parentheses: Home closings (deliveries) : ~11,000 vs. 12,997 (-15%) Average closing price : $580,000 to $590,000 vs. $597,000 (-2% at the midpoint) Home closings gross margin : starting at 20% in Q1 and increasing “gradually throughout the year,” more visibility to come vs. 22.5% Ending active community count : 365 to 370 vs. 341 (+8%) The home closings and average closing price guidance imply revenue in 2026 will decline 17% or so year-over-year. This sharp drop is surprising given the plan for increasi...
Massimo Giachetti/iStock Editorial via Getty Images Today, as the market sells technology to buy stable consumer goods, industrials, and energy, a question arises: is something truly serious about to happen to predominantly technology-based indices like the Nasdaq-100, or is this an opportunity? I ask myself this while looking at the performance of the Invesco NASDAQ 100 ETF ( QQQM ). Fear in the ...
Massimo Giachetti/iStock Editorial via Getty Images Today, as the market sells technology to buy stable consumer goods, industrials, and energy, a question arises: is something truly serious about to happen to predominantly technology-based indices like the Nasdaq-100, or is this an opportunity? I ask myself this while looking at the performance of the Invesco NASDAQ 100 ETF ( QQQM ). Fear in the market is increasing, yet expectations for earnings and revenues ultimately have not changed; they remain at record levels. This creates a valuation gap that is hard to ignore. A gap that I am personally taking into consideration. But before getting into the heart of the matter … What Is QQQM QQQM is a passive ETF that replicates the Nasdaq-100 Index with the objective of tracking the index’s performance before costs and expenses using a full replication modified market-cap weighting methodology. QQQM (Seeking Alpha) This means it is a sort of hybrid between equal weight and market cap weight, setting a maximum limit per single stock of 24% absolute maximum and 15% during the annual reconstitution (December) and quarterly rebalancing. Attention: It can concentrate more than 25% in a single sector. The fund has an expense ratio of 0.15% annually , a practically negligible bid/ask spread (0.01%), and a 6% annual turnover (very low), covered by a minimum yield of 0.51%. Holding distribution There are 100 stocks which , as we well know, show a clear bias toward growth. This is also because the Nasdaq-100 excludes financials. At the same time, it brings an overexposure to technology (51%), which today is the heaviest sector within the index. QQQM has double or triple the technological exposure compared to global indices. And if we were to also consider sectors now regarded as quasi-technological, such as communications and consumer discretionary, we would reach almost 90% exposure to the tech and para-tech segment. QQQM - Holding Breakdown (Seeking Alpha) This leads to extreme c...
Middleby press release ( MIDD ): Q4 Non-GAAP EPS of $2.14. Revenue of $866M (+5% Y/Y) and full year 2026: 1st Qtr, 2026 Full Year 2026 Commercial Foodservice Food Processing Total Company Commercial Foodservice Food Processing Total Company Net sales $560-$578 M $200-210 M $760-788 M $2.37-2.43 B $895-925 M $3.27-3.36 B Growth 1% 22% 6% 2% 7% 4% Organic Growth 1% 10-15% 1-3% 4-6% Adjusted EBITDA $...
Middleby press release ( MIDD ): Q4 Non-GAAP EPS of $2.14. Revenue of $866M (+5% Y/Y) and full year 2026: 1st Qtr, 2026 Full Year 2026 Commercial Foodservice Food Processing Total Company Commercial Foodservice Food Processing Total Company Net sales $560-$578 M $200-210 M $760-788 M $2.37-2.43 B $895-925 M $3.27-3.36 B Growth 1% 22% 6% 2% 7% 4% Organic Growth 1% 10-15% 1-3% 4-6% Adjusted EBITDA $142-152 M $37-41 M $161-173 M $632-658 M $186-208 M $745-780 M Adjusted Earnings Per Share (1) $1.90-2.02 $9.20-9.36 Click to enlarge More on Middleby Middleby Making Smarter Moves, But Weak Industry Demand Is A Significant Overhang The Middleby Corporation (MIDD) M&A Call Transcript The Middleby Corporation (MIDD) 26North Partners LP, - M&A Call - Slideshow Middleby Q4 2025 Earnings Preview Middleby to sell 51% stake in Residential Kitchen business at $885M
Rhythm Pharmaceuticals press release ( RYTM ): Q4 GAAP EPS of -$0.73 beats by $0.07 . Revenue of $57.3M (+37.0% Y/Y) beats by $1.09M . Guidance December 31, 2026 Rhythm anticipates approximately $385 million to $415 million in Non-GAAP operating expenses. Non-GAAP operating
Rhythm Pharmaceuticals press release ( RYTM ): Q4 GAAP EPS of -$0.73 beats by $0.07 . Revenue of $57.3M (+37.0% Y/Y) beats by $1.09M . Guidance December 31, 2026 Rhythm anticipates approximately $385 million to $415 million in Non-GAAP operating expenses. Non-GAAP operating
Nigeria extended a ban on shea nut exports by a year, reinforcing a drive to curb raw commodity shipments and boost local value addition. The extension aims to “deepen processing capacity within Nigeria, enhance livelihoods in shea-producing communities, and promote the growth of Nigerian exports anchored on value-added products,” President Bola Tinubu said in a statement Thursday. Nigeria is tryi...
Nigeria extended a ban on shea nut exports by a year, reinforcing a drive to curb raw commodity shipments and boost local value addition. The extension aims to “deepen processing capacity within Nigeria, enhance livelihoods in shea-producing communities, and promote the growth of Nigerian exports anchored on value-added products,” President Bola Tinubu said in a statement Thursday. Nigeria is trying to shift the shea nut industry from exporting mostly raw produce to processing more high-value products like shea butter and its derivatives, which can fetch prices as much as 20 times higher, according to the presidency. The initiative has been blunted by a lack of processing infrastructure, a large informal trade and enforcement challenges. Prices of the nuts slumped by a third after Nigeria in August joined other producers in West Africa by announcing a moratorium on shipments. They traded at about 850 naira (63 US cents) a kilogram at the end of the harvest season in December, according to Lagos-based commodities exchange AFEX. Read More: Shea Nut Prices Plunge After Nigeria Bans Exports The production of shea butter in Nigeria is dominated by smallholders and women in rural villages in central Nigeria, where a growing number of attacks by extremists groups are devastating local communities. Intermediaries who move products from smallholders to markets have also left the trade after the ban came into effect, resulting in lost contracts, the National Shea Products Association of Nigeria told a local newspaper . Slow-growing shea trees are indigenous to west and central Africa, with Nigeria producing about 500,000 tons of the fruit annually and accounting for 40% of global supply that’s valued at $6.5 billion, according to the government. Burkina Faso, Ghana, Mali, Ivory Coast and Togo — all of which restrict exports to promote domestic processing — are the other main producers. Shea butter can be used as a substitute for cocoa butter and US regulators have granted app...
bit245/iStock via Getty Images CAVA Group ( CAVA ) is a company I like. It still has a lot of room to grow, few stores, but they have already proven profitable, a large addressable market, everything you want to see from a company in the
bit245/iStock via Getty Images CAVA Group ( CAVA ) is a company I like. It still has a lot of room to grow, few stores, but they have already proven profitable, a large addressable market, everything you want to see from a company in the
jmmf/iStock via Getty Images Thesis Galapagos NV ( GLPG ) reported a FY25 GAAP EPS of €4.87 and revenue of about €1.11 billion. Now, this figure is up about 303% year over year, but we have to keep in mind that it is largely reflecting
jmmf/iStock via Getty Images Thesis Galapagos NV ( GLPG ) reported a FY25 GAAP EPS of €4.87 and revenue of about €1.11 billion. Now, this figure is up about 303% year over year, but we have to keep in mind that it is largely reflecting
KenWiedemann/iStock Unreleased via Getty Images Last month, I was in Ann Arbor to teach a class on REIT investing at the University of Michigan: I was fortunate to get this opportunity thanks to Joey Agree, the CEO of Agree Realty Corporation ( ADC ), who connected
KenWiedemann/iStock Unreleased via Getty Images Last month, I was in Ann Arbor to teach a class on REIT investing at the University of Michigan: I was fortunate to get this opportunity thanks to Joey Agree, the CEO of Agree Realty Corporation ( ADC ), who connected